Evidence map›Paper›PMID 40718483›Full record

ArticleFrontiers in immunology2025

Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report.

Yoshihito Kitamura, Seiichi Shimizu, Shintaro Kuroda, Naruhiko Honmyo, Ryosuke Nakano, Hiroshi Sakai, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Tsuyoshi Kobayashi and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yoshihito KitamuraDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Seiichi ShimizuDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Shintaro KurodaDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Naruhiko HonmyoDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Ryosuke NakanoDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Hiroshi SakaiDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Hiroyuki TaharaDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Masahiro OhiraDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Kentaro IdeDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Tsuyoshi KobayashiDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a rare hematological immune-related adverse event (irAE) induced by durvalumab, an immune checkpoint inhibitor, after conversion surgery in a patient with intrahepatic cholangiocarcinoma (ICC). A 72-year-old male was admitted for recurrent ICC treatment in the posterior sector. The primary treatment chosen was systemic chemotherapy with durvalumab combined with gemcitabine and cisplatin. After eight cycles of chemotherapy, partial hepatectomy was performed against three nodules of ICC at liver segments 6 and 7 as conversion surgery. Approximately 3 months after the last injection of durvalumab, the patient was readmitted to our department due to a high fever. The number of neutrophils dropped to zero. Despite daily administration of granulocyte colony-stimulating factor, the patient had agranulocytosis with neutrophil counts remaining between 0 and 80/µL for 16 days. The results of the bone marrow biopsy indicated that the patient had cytotoxicity due to autoimmunity against the common progenitor cells of granulocytes and monocytes as an adverse reaction to durvalumab. The patient was diagnosed with immune-related neutropenia and started on steroid bolus therapy. Four days after initiating steroid therapy, the neutrophil count began to improve, reaching 1540/µL after 7 days, and remained stable thereafter. This case highlights the potential for durvalumab-induced immune-related agranulocytosis following conversion surgery in a patient with ICC, emphasizing the importance of careful monitoring and timely management of irAEs, particularly in the context of postoperative infections.

Indexed as

AgranulocytosisAntibodies, MonoclonalBile Duct NeoplasmsCholangiocarcinomaImmune Checkpoint InhibitorsAgedHepatectomyHumansMaleAntibodies, MonoclonaldurvalumabImmune Checkpoint Inhibitorsagranulocytosisconversion surgerydurvalumabimmune-related adverse eventintrahepatic cholangiocarcinoma

Identifiers

PMID40718483
PMCPMC12289667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.